JP2023529214A - エリスロポエチン産生肝細胞受容体ａ２（ｅｐｈａ２）の過剰発現を特徴とする疾患の治療 - Google Patents

エリスロポエチン産生肝細胞受容体ａ２（ｅｐｈａ２）の過剰発現を特徴とする疾患の治療 Download PDF

Info

Publication number
JP2023529214A
JP2023529214A JP2022575977A JP2022575977A JP2023529214A JP 2023529214 A JP2023529214 A JP 2023529214A JP 2022575977 A JP2022575977 A JP 2022575977A JP 2022575977 A JP2022575977 A JP 2022575977A JP 2023529214 A JP2023529214 A JP 2023529214A
Authority
JP
Japan
Prior art keywords
cancer
epha2
patient
tumor
tumor tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022575977A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023529214A5 (cg-RX-API-DMAC7.html
Inventor
ギャビン ベネット，
スティーブン ブレイクモア，
カーリー キャンベル，
マイケル リグビー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BicycleTx Ltd
Original Assignee
BicycleTx Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BicycleTx Ltd filed Critical BicycleTx Ltd
Publication of JP2023529214A publication Critical patent/JP2023529214A/ja
Publication of JP2023529214A5 publication Critical patent/JP2023529214A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2022575977A 2020-06-12 2021-06-11 エリスロポエチン産生肝細胞受容体ａ２（ｅｐｈａ２）の過剰発現を特徴とする疾患の治療 Pending JP2023529214A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063038279P 2020-06-12 2020-06-12
US63/038,279 2020-06-12
PCT/GB2021/051451 WO2021250418A1 (en) 2020-06-12 2021-06-11 Treatment of diseases characterized by overexpression of erythropoietin-producing hepatocellular receptor a2 (epha2)

Publications (2)

Publication Number Publication Date
JP2023529214A true JP2023529214A (ja) 2023-07-07
JP2023529214A5 JP2023529214A5 (cg-RX-API-DMAC7.html) 2024-06-19

Family

ID=76641715

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022575977A Pending JP2023529214A (ja) 2020-06-12 2021-06-11 エリスロポエチン産生肝細胞受容体ａ２（ｅｐｈａ２）の過剰発現を特徴とする疾患の治療

Country Status (10)

Country Link
US (1) US20230233698A1 (cg-RX-API-DMAC7.html)
EP (1) EP4165414A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023529214A (cg-RX-API-DMAC7.html)
KR (1) KR20230065231A (cg-RX-API-DMAC7.html)
CN (1) CN115698720A (cg-RX-API-DMAC7.html)
AU (1) AU2021289095A1 (cg-RX-API-DMAC7.html)
CA (1) CA3180095A1 (cg-RX-API-DMAC7.html)
IL (1) IL298868A (cg-RX-API-DMAC7.html)
MX (1) MX2022015419A (cg-RX-API-DMAC7.html)
WO (1) WO2021250418A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ731185A (en) 2014-10-29 2024-03-22 Bicyclerd Ltd Bicyclic peptide ligands specific for mt1-mmp
WO2019002842A1 (en) 2017-06-26 2019-01-03 Bicyclerd Limited BICYCLIC PEPTIDE LIGANDS WITH DETECTABLE FRACTIONS AND USES THEREOF
JP7670481B2 (ja) 2017-08-04 2025-04-30 バイスクルテクス・リミテッド Ｃｄ１３７に対して特異的な二環式ペプチドリガンド
GB201721265D0 (en) 2017-12-19 2018-01-31 Bicyclerd Ltd Bicyclic peptide ligands specific for EphA2
TWI825046B (zh) 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Epha2特用之雙環胜肽配位基
CA3091775A1 (en) 2018-02-23 2019-08-29 Bicycletx Limited Multimeric bicyclic peptide ligands
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
GB201810316D0 (en) 2018-06-22 2018-08-08 Bicyclerd Ltd Peptide ligands for binding to EphA2
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
WO2020128527A1 (en) 2018-12-21 2020-06-25 Bicyclerd Limited Bicyclic peptide ligands specific for pd-l1
EP3897849A1 (en) 2018-12-21 2021-10-27 BicycleTx Limited Bicyclic peptide ligands specific for pd-l1
GB201900529D0 (en) 2019-01-15 2019-03-06 Bicycletx Ltd Bicyclic peptide ligands specific for CD38
KR20220007098A (ko) 2019-05-09 2022-01-18 바이사이클티엑스 리미티드 Ox40에 특이적인 이환식 펩티드 리간드
TWI860386B (zh) 2019-07-30 2024-11-01 英商拜西可泰克斯有限公司 異質雙環肽複合物
CN116348476A (zh) 2020-08-03 2023-06-27 拜斯科技术开发有限公司 基于肽的接头

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008529497A (ja) * 2005-02-04 2008-08-07 レイベン バイオテクノロジーズ，インコーポレイティド ＥｐｈＡ２に結合する抗体およびその使用方法
US20110281279A1 (en) * 2007-12-21 2011-11-17 Siemens Healthcare Diagnostics Inc. CIRCULATING Epha2 RECEPTOR
JP2019512477A (ja) * 2016-03-16 2019-05-16 メリマック ファーマシューティカルズ インコーポレーティッド エフリン受容体ａ２（ｅｐｈａ２）のナノリポソーム標的化及び関連する診断
WO2019122863A1 (en) * 2017-12-19 2019-06-27 Bicycletx Limited Bicyclic peptide ligands specific for epha2

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101918844A (zh) * 2007-06-18 2010-12-15 米迪缪尼有限公司 表达epha2和erbb2的细胞的协同治疗
JP6074574B2 (ja) 2008-02-05 2017-02-08 バイシクル セラピューティクス リミテッド 方法及び組成物
CA2847245A1 (en) * 2011-09-09 2013-03-14 Amgen Inc. Use of c-met protein for predicting the efficacy of anti-hepatocyte growth factor ("hgf") antibodies in esophageal and gastric cancer patients
WO2016171242A1 (ja) * 2015-04-24 2016-10-27 第一三共株式会社 Ｅｐｈａ２の検出
GB201721265D0 (en) 2017-12-19 2018-01-31 Bicyclerd Ltd Bicyclic peptide ligands specific for EphA2
CN109700812A (zh) * 2019-01-18 2019-05-03 厦门大学 一种治疗表达parp10的肝细胞癌的药物组合物及其应用
US20220184222A1 (en) * 2019-04-02 2022-06-16 Bicycletx Limited Bicycle toxin conjugates and uses thereof
CN114760988A (zh) * 2019-11-27 2022-07-15 拜斯科技术开发有限公司 对EphA2具有特异性的双环肽配体和其用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008529497A (ja) * 2005-02-04 2008-08-07 レイベン バイオテクノロジーズ，インコーポレイティド ＥｐｈＡ２に結合する抗体およびその使用方法
US20110281279A1 (en) * 2007-12-21 2011-11-17 Siemens Healthcare Diagnostics Inc. CIRCULATING Epha2 RECEPTOR
JP2019512477A (ja) * 2016-03-16 2019-05-16 メリマック ファーマシューティカルズ インコーポレーティッド エフリン受容体ａ２（ｅｐｈａ２）のナノリポソーム標的化及び関連する診断
WO2019122863A1 (en) * 2017-12-19 2019-06-27 Bicycletx Limited Bicyclic peptide ligands specific for epha2

Also Published As

Publication number Publication date
AU2021289095A1 (en) 2023-01-05
US20230233698A1 (en) 2023-07-27
CN115698720A (zh) 2023-02-03
WO2021250418A1 (en) 2021-12-16
KR20230065231A (ko) 2023-05-11
EP4165414A1 (en) 2023-04-19
IL298868A (en) 2023-02-01
MX2022015419A (es) 2023-03-17
CA3180095A1 (en) 2021-12-16

Similar Documents

Publication Publication Date Title
CN115698720A (zh) 特征在于促红细胞生成素产生肝细胞受体a2(epha2)的过表达的疾病的治疗
JP2020152726A (ja) 細胞透過性Ｂｃｌ−ｘＬ阻害剤との抗体薬物コンジュゲート
JP2020128378A (ja) Ｂｃｌ−ｘＬ阻害性化合物およびこれを含む抗体薬物コンジュゲート
JP2025509732A (ja) ターゲティングされた二官能性分解剤
EP3676268A1 (en) Heterobifunctional compounds with improved specificityfor the bromodomain of brd4
WO2023056443A1 (en) Binders of cereblon and methods of use thereof
CN116261454A (zh) 转录激活蛋白的咪唑并哌嗪抑制剂
US20230039711A1 (en) Ahr inhibitors and uses thereof
KR20250010706A (ko) 리간드-약물 접합체 및 이의 용도
EP4631956A1 (en) Linker, linker-containing antibody drug conjugate, and preparation method therefor and use thereof
WO2018236781A2 (en) Targeted therapeutics
US12612431B2 (en) Cyclic compounds for treating cancer
JP2026515434A (ja) 抗体－薬物コンジュゲートおよびその使用
CA3233083A1 (en) Small molecules for dot1l degradation and uses thereof
CA3224123A1 (en) Small molecule inhibition of deubiquitinating enzyme josephin domain containing 1 (josd1) as a targeted therapy for leukemias with mutant janus kinase 2 (jak2)
WO2025125652A1 (en) Combination therapy for use in treating cancer
CN121969398A (zh) 抗体偶联药物及其用途

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20230221

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240611

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240611

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250327

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250401

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250619

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250930

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251223

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260216

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260721